Biosearch Life has presented the results from the study with its strain Lactobacillus fermentum CECT5716 for the reduction of the breast pain in women during lactation.
The World Health Organisation recommends exclusive breastfeeding up to 6 months of age as breastmilk provides all the nutrients and components necessary for proper infant development and growth. It is especially during the first weeks of breastfeeding that women can experience various uncomfortable breastfeeding problems such as breast and nipple pain, nipple cracks, and mastitis. These problems make lactation difficult and in some cases lead to the cessation of breastfeeding.
The aim of this study was to evaluate the efficacy of three different doses of L. fermentum CECT5716 in the reduction of the Staphylococcus load in the breastmilk of women suffering from painful breastfeeding.
The study has been elaborated with the data from 98 women divided in 4 groups. Three of these groups received the probiotic strain for 3 weeks at doses of 3 x 109 CFU/day, 6 x 109 CFU/day and 9 x 109 CFU/day respectively. The fourth group (the control group) received a placebo. The evolution of the symptoms was evaluated at 0, 1, 2 and 3 weeks of treatment.
Several important conclusions have been obtained from this study:
- A significant difference in the pain score was observed among the groups receiving the three probiotic doses compared with the control group (p = 0.035, p = 0.000, and p = 0.028, respectively).
- The intake of Lactobacillus significantly reduced the Staphylococcus load in breastmilk. This reduction in the bacterial load induced by the administration of L. fermentum CECT5716 significantly reduced breast pain in women and demonstrated that the effects were noticeable from the first week of treatment. Besides, L. fermentum CECT5716, as demonstrated in previous studies, possesses immunomodulatory capabilities which may contribute to the effect of the strain on mastitis.
- Prior to the intervention, most women in the study described their pain with adjectives related to anger, fear, and anxiety. The Lactobacillus treatment significantly improved this assessment in those women. This is an important aspect of the study because the emotional distress caused by mastitis can lead to the cessation of breastfeeding.
- The current dosing of lactobacilli, at a level of 3 x 109 CFU/day is effective and sufficient to produce a decrease in staphylococcal load in breastmilk leading to improvement in pain symptoms in women suffering from breast pain associated with Staphylococcus in the breastmilk.
- L. fermentum CECT5716 is an efficient treatment for breast pain during lactation associated with a high level of Staphylococcus in breastmilk.
Previous studies demonstrated the capability of certain Lactobacillus strains to reduce the bacterial load in the breastmilk of women suffering mastitis. One of these strains is Lactobacilus fermentum CECT5716, a strain isolated from human milk.
Biosearch Life has identified and isolated several novel human milk bacteria with probiotic activity, involved in the protection and well-being of the lactating baby and adults. Human breast milk strains have been selected from hundreds of different strains for their excellent capabilities and probiotic properties, and for their scientifically proven health benefits.
Biosearch Life is a leader in biotechnology with a global innovative vocation, bringing innovation in healthy natural ingredients integrating his research, development, production and marketing capacities around three product platforms: Omega-3 (Eupoly-3®), Probiotics (Hereditum®), Plant Extracts (Exxentia®).
It provides complete solutions to clients in over thirty countries for those looking for maximum satisfaction with custom solutions and a solid portfolio of over 200 products. The company’s strategy has been based on constant innovation. Child nutrition, Functional dairy and Women’s health are the segments in which the company wants to be a benchmark.